Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Osteonecrosis of the jaw—a potential adverse effect of bisphosphonate treatment

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. Mashiba T et al. (2005) The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab 23 (Suppl): 36–42

    Article  CAS  Google Scholar 

  2. Komatsubara S et al. (2004) Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J Bone Miner Res 19: 999–1005

    Article  CAS  Google Scholar 

  3. Komatsubara S et al. (2003) Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res 18: 512–520

    Article  CAS  Google Scholar 

  4. Burr DB et al. (2003) Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs. Bone 33: 960–969

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Dieter Felsenberg.

Ethics declarations

Competing interests

The author has received research support and consultation fees from the following companies: Amgen, Bayer, Chugai, Eli Lilly, GlaxoSmithKline, Gry-Pharma, Merck Sharpe & Dohme, Novartis, Nycomed, Organon, OttoBock, Pfizer, Procter & Gamble, Roche, Schering, Servier, Symarc, Teva, and Wyeth.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Felsenberg, D. Osteonecrosis of the jaw—a potential adverse effect of bisphosphonate treatment. Nat Rev Endocrinol 2, 662–663 (2006). https://doi.org/10.1038/ncpendmet0348

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0348

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing